Fellows who have successfully completed three years of an ACGME-accredited pediatric residency or an RCPSC-accredited residency program located in Canada are eligible to participate in this training program. The selection process is competitive, and fellows are selected in part on the basis of their interest in developing careers in academic medicine. Successful completion of this three-year ACGME accredited program will lead to ABP board eligibility in Pediatric Hematology Oncology. The selection process is competitive, and fellows are selected in part on the basis of their interest in developing careers in academic medicine. Successful completion of this three-year ACGME accredited program will lead to ABP board eligibility in Pediatric Hematology Oncology.
Once accepted to our program, the following items are required before starting the fellowship:
- Washington state medical license: The State of Washington and the UW School of Medicine require that all physicians beyond their internship year have full license to practice medicine. Fellows who do not have a Washington license upon their arrival will not be permitted to begin their training and will not be paid. Information regarding licensure deadlines, reciprocal licensure and application forms may be obtained from the Washington State Department of Health, Professional Licensing Division by calling 360-236-4700, or writing PO Box 47866, Olympia, Washington 98504-7866. Online application forms are available at: http://www.doh.wa.gov/LicensesPermitsandCertificates/MedicalCommission/MedicalLicensing.aspx
- DEA certificate: Upon receiving their Washington State Department of Health issued MD license, the fellow must apply for a DEA license. The fellow will submit their completed application to the University of Washington GME office for processing. This will be a limited license that cannot be used outside the scope of the fellowship program. Information regarding DEA can be found at: http://www.deadiversion.usdoj.gov/drugreg/reg_apps/index.html
Click here to review other first year requirements for this program.
Applications for the Pediatric Hematology/Oncology fellowship program commencing July 1, 2017 must be made through ERAS. The MyERAS website opens to applicants to begin working on their applications on July 1, 2015. Applicants can submit their applications beginning November 15, 2015.
We require a minimum of three letters of recommendation with one to come from your residency program director and request that your personal statement be one page in length. Applicants must also register with the National Resident Matching Program (NRMP).
Our program’s deadline for ERAS applications is January 15, 2016. Please be sure all requested materials are part of your ERAS file at the time you submit your application to ERAS so the reviewers will have access to complete information about you. Incomplete applications (i.e., missing letters of reference, USMLE scores) will NOT be forwarded to the selection committee until complete.
We are one of the longest standing NCI-funded pediatric training programs. Our Fellowship Program is funded by a T32 training grant from the National Cancer Institute. The initial year of fellowship funding and funding required beyond that supported by the T32 training grant are provided through institutional sources and the generosity of the Kiwanis Childhood Cancer Program. Due to the number of positions in our program supported by the T32 training grant, the majority of our trainees must be U.S. citizens or green card holders. We will consider applications from J-1 visa-holders, but those positions are limited. We do not sponsor H1B visa applications.
Fellows supported by a T32 training grant have a unique benefit package, e.g. they are not eligible to participate in the University retirement plan or flexible spending accounts, and taxation rules vary.
Foreign national physicians who are not citizens of the US and do not hold Permanent Resident status will need to secure a visa prior to commencement of training in a University of Washington residency or fellowship training program. Information on visas approved for trainees in our programs is outlined in the GME Visa Policy.
Following is a list of important information for residents/fellows sponsored on a J-1 visa:
- ECFMG J-1 Visa Sponsorship Fact Sheet: Outlines eligibility requirements for J-1 visa sponsorship, including ECFMG Certification, duration of participation, and two-year home requirement.
- EVSP Reference Guide: Contains important information on the application process, visa issuance, travel, and maintenance of status.
- Application Materials for J-1 Sponsorship: All application materials must be sent to the Training Program Liaison (TPL) in the GME Office for review and processing. The TPL acts as an intermediary between the ECFMG and the program/exchange visitor, and communicates with the ECFMG on all matters pertaining to J-1 visa sponsorship.
- Exchange Visitor Sponsorship Program FAQs
- J-1 Visa Processing Instructions: Documents that outline how to apply for the visa once approved for J-1 sponsorship, and how to maintain visa status.
- Validation of Initial Arrival Form: The ECFMG must confirm the initial arrival to the US of J-1 physicians in the government database (SEVIS) within 30 days of the training start date. Trainees must bring this form (which will be included with the initial DS-2019 paperwork) to the TPL as soon as they arrive in Seattle. Delays in submitting the validation paperwork may cause delays in issuance of the physician’s SSN.
- Travel: The Travel information page on the ECFMG web site contains important information that J-1 physicians need to know prior to traveling outside the US. Note: J-1 exchange visitor must have a travel validated DS-2019 prior to traveling outside the US.
We do not sponsor H-1B visas.
For 2016 we have designated the following group interview dates.
Friday, February 26
Tuesday, March 1
Friday, March 4
Tuesday, March 15
Friday, March 18
Tuesday, March 22
Friday, March 25
We will schedule 3-4 people for each group interview date. Please submit questions to Barbara Killam.
January 15, 2016